These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 26820629)

  • 41. Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers.
    Kim YY; Park MS; Aljoqiman KS; Choi JY; Kim MJ
    Clin Mol Hepatol; 2019 Sep; 25(3):223-233. PubMed ID: 30661336
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Application of Liver Imaging Reporting and Data System version 2018 ancillary features to upgrade from LR-4 to LR-5 on gadoxetic acid-enhanced MRI.
    Lee S; Kim SS; Bae H; Shin J; Yoon JK; Kim MJ
    Eur Radiol; 2021 Feb; 31(2):855-863. PubMed ID: 32809162
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study.
    Joo I; Kim SY; Kang TW; Kim YK; Park BJ; Lee YJ; Choi JI; Lee CH; Park HS; Lee K; Kim H; Yu E; Kang HJ; Ha SY; Kim JY; Ahn S; Jung ES; Kim BH; Han HS; Lee JM
    Radiology; 2020 Aug; 296(2):335-345. PubMed ID: 32484414
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Focal lesions in the cirrhotic liver: their pivotal role in gadoxetic acid-enhanced MRI and recognition by the Western guidelines.
    Golfieri R; Garzillo G; Ascanio S; Renzulli M
    Dig Dis; 2014; 32(6):696-704. PubMed ID: 25376286
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis.
    Kim AY; Kim YK; Lee MW; Park MJ; Hwang J; Lee MH; Lee JW
    Acta Radiol; 2012 Oct; 53(8):830-8. PubMed ID: 22847903
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Subcentimeter hepatocellular carcinoma in treatment-naïve patients: noninvasive diagnostic criteria and tumor staging on gadoxetic acid-enhanced MRI.
    Hwang SH; Hong SB; Park S; Han K; Park YN; Kim SY; Park MS
    Eur Radiol; 2021 Apr; 31(4):2321-2331. PubMed ID: 33044650
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules ≤2 cm in cirrhosis.
    Ayuso C; Forner A; Darnell A; Rimola J; García-Criado Á; Bianchi L; Vilana R; Oliveira R; Llarch N; Bruix J
    Liver Int; 2019 Jul; 39(7):1281-1291. PubMed ID: 31077539
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
    Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evidence of diagnostic enhancement pattern in hepatocellular carcinoma nodules ≤2 cm according to the AASLD/EASL revised criteria.
    Quaia E; De Paoli L; Angileri R; Pizzolato R; Cabibbo B; Cova MA
    Abdom Imaging; 2013 Dec; 38(6):1245-53. PubMed ID: 24026173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Added value of smooth hypointense rim in the hepatobiliary phase of gadoxetic acid-enhanced MRI in identifying tumour capsule and diagnosing hepatocellular carcinoma.
    An C; Rhee H; Han K; Choi JY; Park YN; Park MS; Kim MJ; Park S
    Eur Radiol; 2017 Jun; 27(6):2610-2618. PubMed ID: 27770230
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of subcentimetre arterially enhancing and hepatobiliary hypointense lesions on gadoxetic acid-enhanced MRI in patients at risk for HCC.
    Park CJ; An C; Park S; Choi JY; Kim MJ
    Eur Radiol; 2018 Apr; 28(4):1476-1484. PubMed ID: 29063251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance.
    Marks RM; Ryan A; Heba ER; Tang A; Wolfson TJ; Gamst AC; Sirlin CB; Bashir MR
    AJR Am J Roentgenol; 2015 Mar; 204(3):527-35. PubMed ID: 25714281
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease.
    Lee SE; An C; Hwang SH; Choi JY; Han K; Kim MJ
    Eur Radiol; 2018 Apr; 28(4):1551-1559. PubMed ID: 29134355
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MR imaging features for improved diagnosis of hepatocellular carcinoma in the non-cirrhotic liver: Multi-center evaluation.
    Fischer MA; Raptis DA; Donati OF; Hunziker R; Schade E; Sotiropoulos GC; McCall J; Bartlett A; Bachellier P; Frilling A; Breitenstein S; Clavien PA; Alkadhi H; Patak MA
    Eur J Radiol; 2015 Oct; 84(10):1879-87. PubMed ID: 26194029
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combining the Arterial Phase of Contrast-Enhanced Ultrasonography, Gadoxetic Acid-Enhanced Magnetic Resonance Imaging and Diffusion-Weighted Imaging in the Diagnosis of Hepatic Nodules ≤20 mm in Patients with Cirrhosis.
    Zhou Y; Jing X; Zhang X; Ding J; Wang Y; Zhou H; Zhang Q; Chen Y; Yue W
    Ultrasound Med Biol; 2019 Mar; 45(3):693-701. PubMed ID: 30606633
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC.
    Kim YK; Lee WJ; Park MJ; Kim SH; Rhim H; Choi D
    Radiology; 2012 Oct; 265(1):104-14. PubMed ID: 22891358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Presence of a hypovascular hepatic nodule showing hypointensity on hepatocyte-phase image is a risk factor for hypervascular hepatocellular carcinoma.
    Ichikawa S; Ichikawa T; Motosugi U; Sano K; Morisaka H; Enomoto N; Matsuda M; Fujii H; Araki T
    J Magn Reson Imaging; 2014 Feb; 39(2):293-7. PubMed ID: 23633285
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The usefulness of gadoxetic acid-enhanced dynamic magnetic resonance imaging in hepatocellular carcinoma: toward improved staging.
    Choi SH; Byun JH; Kwon HJ; Ha HI; Lee SJ; Kim SY; Won HJ; Kim PN
    Ann Surg Oncol; 2015 Mar; 22(3):819-25. PubMed ID: 25201507
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.
    Ahn SS; Kim MJ; Lim JS; Hong HS; Chung YE; Choi JY
    Radiology; 2010 May; 255(2):459-66. PubMed ID: 20413759
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gadoxetic acid-enhanced MRI for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase.
    Iannicelli E; Di Pietropaolo M; Marignani M; Briani C; Federici GF; Delle Fave G; David V
    Radiol Med; 2014 Jun; 119(6):367-76. PubMed ID: 24297598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.